Relapsing Forms of Multiple Sclerosis: Clinical Trials

2 trials for Relapsing Forms of Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow Relapsing Forms of Multiple Sclerosis: new trials by email Literature Review of Relapsing Forms of Multiple Sclerosis trials Research Report on Relapsing Forms of Multiple Sclerosis

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
BIIB091, DRF, Placebo - Relapsing Forms of Multiple Sclerosis
Phase 2CompletedBiogen1272023-07-252026-02-20
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine - Relapsing Forms of Multiple Sclerosis
Phase 2CompletedBiogen712015-02-282017-06-02

Narrower conditions

Multiple Sclerosis (1)

Broader conditions

Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Nervous System Diseases (1)

Interventions

23-valent pneumococcal capsular polysaccharide vaccine (1)  ·  BIIB091 (1)  ·  Dimethyl Fumarate (1)  ·  Diphtheria-Tetanus Vaccine (1)  ·  Meningococcal Vaccines (1)

Sponsors

Biogen (2)

Countries

United States (2)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Germany (1)  ·  Italy (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  Romania (1)  ·  Spain (1)  ·  Switzerland (1)

Results publications

PMID 29159204